STAT October 22, 2024
This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox.
Good morning. Check out the latest promo we’re running, where you can get your first three months of a STAT+ subscription for $20.
Onto the biotech news today.
The need-to-know this morning
- In an effort to reduce spending, Editas Medicine said it plans to seek a partner to continue the development of its CRISPR-based treatment for sickle cell disease and beta thalassemia. The company is shifting focus to an experimental treatment, still in animal testing, that performs the CRISPR editing inside the body.
Pfizer’s and Lilly’s telehealth ties under scrutiny
A group of...
Today's Sponsors
Today's Sponsor